160 related articles for article (PubMed ID: 20621877)
1. New drugs: pitavastatin calcium, vigabatrin, and romidepsin.
Hussar DA; Christian ME
J Am Pharm Assoc (2003); 2010; 50(4):548-51. PubMed ID: 20621877
[No Abstract] [Full Text] [Related]
2. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M
Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
[TBL] [Abstract][Full Text] [Related]
4. Drug approved to treat infantile spasms.
Thompson CA
Am J Health Syst Pharm; 2009 Oct; 66(19):1682. PubMed ID: 19767370
[No Abstract] [Full Text] [Related]
5. Vigabatrin administration in patients with infantile spasms: the risks.
Jaseja H
Clin Neurol Neurosurg; 2010 Nov; 112(9):835. PubMed ID: 20934097
[No Abstract] [Full Text] [Related]
6. Romidepsin Therapy Over 5 Years in a Clinical Setting-Real-world Experience.
Bates SE; Geskin LJ
JAMA Oncol; 2016 Jun; 2(6):794-5. PubMed ID: 27054784
[No Abstract] [Full Text] [Related]
7. Histone deacetylase inhibitors: novel agents in cancer treatment.
Glass E; Viale PH
Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.
Frye R; Myers M; Axelrod KC; Ness EA; Piekarz RL; Bates SE; Booher S
Clin J Oncol Nurs; 2012 Apr; 16(2):195-204. PubMed ID: 22459529
[TBL] [Abstract][Full Text] [Related]
9. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Grant C; Rahman F; Piekarz R; Peer C; Frye R; Robey RW; Gardner ER; Figg WD; Bates SE
Expert Rev Anticancer Ther; 2010 Jul; 10(7):997-1008. PubMed ID: 20645688
[TBL] [Abstract][Full Text] [Related]
10. Vigabatrin therapy in infantile spasms: solving one problem and inducing another?
Wohlrab G; Leiba H; Kästle R; Ramelli G; Schmitt-Mechelke T; Schmitt B; Landau K
Epilepsia; 2009 Aug; 50(8):2006-8. PubMed ID: 19682036
[No Abstract] [Full Text] [Related]
11. Therapy of infantile spasms: new opportunities and emerging challenges.
Mikati MA; Cornett KM
Epilepsy Behav; 2010 Apr; 17(4):571-3. PubMed ID: 20097137
[No Abstract] [Full Text] [Related]
12. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
[TBL] [Abstract][Full Text] [Related]
13. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
Thaler F
Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
[TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
[TBL] [Abstract][Full Text] [Related]
15. Deal watch: Celgene acquires Gloucester pharmaceuticals, gaining approved HDAC inhibitor.
Nat Rev Drug Discov; 2010 Feb; 9(2):94. PubMed ID: 20118955
[No Abstract] [Full Text] [Related]
16. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
17. Pitavastatin (Livalo)--the seventh statin.
Med Lett Drugs Ther; 2010 Jul; 52(1343):57-8. PubMed ID: 20651638
[No Abstract] [Full Text] [Related]
18. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Jain N; Odenike O
Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
[TBL] [Abstract][Full Text] [Related]
20. Romidepsin in the treatment of T-cell lymphoma: profile report.
Yang LP
BioDrugs; 2011 Dec; 25(6):393-5. PubMed ID: 22050341
[No Abstract] [Full Text] [Related]
[Next] [New Search]
